BLUE shares jumped 14% after recent FDA approval, price target upgrades

Shares of Bluebird Bio (BLUE) are trading 14% higher at a price of $6.735 at the time of this writing. While it's generally been a somewhat gloomy day for this part of the market, the company is rapidly outpacing it's peers in the Health Care sector.

- Bluebird Bio gets accelerated approval for Skysona gene therapy for cerebral adrenoleukodystrophy
- The therapy costs $3 million
- Bluebird bio PT is raised to $9 at BofA Securities

Bluebird Bio has been trading between a 52-week high of $17.85 and a 52-week low of $2.87. The stock has a market cap of $519 Million.

bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.